Abstract 376P
Background
This study aimed to explore the beneficial of intensive nutrition intervention with intensity-modulated radiotherapy and concurrent cisplatin-based chemotherapy in the treatment of patients with locally advanced nasopharyngeal carcinoma.
Methods
174 locally advanced nasopharyngeal carcinoma patients (LANPC) receiving radical radiotherapy and concurrent cisplatin-based chemotherapy were enrolled from December, 2000 to December, 2016. Patients were divided into two groups as NI group(which received intensive, individualized nutrition education counseling and oral supplements if required), and UC group (general advice and nutrition booklet, without nutrition education). Propensity score matching was performed to balance the baseline differences between the two groups.
Results
Following one-to-one propensity score matching, survival outcomes for the matched data set indicated that the NI group achieved higher overall survival and failure-free survival (P<0.05) compared with UC. Subgroup analysis revealed that NI was associated with significantly improved OS (Hazard ratio [HR] =1.577, 95% Confidence interval [CI] = 1.055–2.357, P < 0.05) and FFS (HR = 1.53, 95% CI = 1.022–2.29, P<0.05). Additionally, the differences of the main adverse reactions after treatment between the two group were not statistically significant (P>0.05).
Conclusions
Early and intensive NI promoted beneficial outcomes in ameliorating the prognosis in loco-regionally advanced NPC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
250P - Impact of adjuvant chemo(radio)therapy in stage I/II testicular seminoma
Presenter: Mahmoud Eleisawy
Session: Poster Display
Resources:
Abstract
251P - LDH isozyme as a prognostic factor for patients with metastatic clear cell renal cell carcinoma (mCRCC)
Presenter: Hayato Takeda
Session: Poster Display
Resources:
Abstract
252P - Risk factors for recurrence after curative nephrectomy in non-metastatic renal cell carcinoma: A retrospective cohort study
Presenter: Kristine Tejada
Session: Poster Display
Resources:
Abstract
253TiP - WUTSUP-02-II-Neo-Dis-Tis: Investigating the efficacy and safety of neoadjuvant tislelizumab plus disitamab vedotin with adjuvant tislelizumab in upper urinary tract carcinoma: A phase II multi-center study
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
254TiP - Prospective observational trial of cabozantinib plus nivolumab in Japanese patients with advanced or metastatic renal cell carcinoma: JACUMET trial
Presenter: Yuji Miura
Session: Poster Display
Resources:
Abstract
264P - Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Chia-Chi Lin
Session: Poster Display
Resources:
Abstract
266P - Clinical application and potential impact of liquid biopsy on the management of Chinese patients with metastatic castration-resistant prostate cancer (mCRPC): A territory-wide prospective analysis
Presenter: Wai Kay Philip Kwong
Session: Poster Display
Resources:
Abstract
267P - Exploring homologous recombination deficiency threshold for predicting response to PARP inhibitor in prostate cancer
Presenter: Diwei Zhao
Session: Poster Display
Resources:
Abstract
268P - Comparisons of on new-onset prostate cancer in type 2 diabetes mellitus exposed to the SGLT2I and DPP4I: A population-based cohort study
Presenter: Hou In Chou
Session: Poster Display
Resources:
Abstract
269P - Prostate cancer harboring low COMT expression correlates with a poor prognosis and response to enzalutamide
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract